S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast

Current Cancer Drug Targets

Volumn 8, Issue 4, 2008, Pages 243-252

  Arai, Kazumori ^a   Takano, Sachiko ^b   Teratani, Takumi ^c   Ito, Yasuhiro ^d   Yamada, Toshihiro ^a   Nozawa, Ryushi ^b  

^a SHIZUOKA GENERAL HOSPITAL   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d KUMA HOSPITAL   (Japan)

Author keywords

Breast; Ductal carcinoma; Histopathology; Immunohistochemistry; S100 protein; S100A8; S100A9

Indexed keywords

CALGRANULIN A; CALGRANULIN B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN;

ARTICLE; BREAST CARCINOMA; CANCER STAGING; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MITOSIS RATE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CALGRANULIN A; CALGRANULIN B; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 45849119823     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908784533445     Document Type: Article

References (46)

1. Marenholz, I.; Heizmann, C. W.; Fritz, G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 2004, 322, 1111-1122.
2. Donato, R. Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 2003, 60, 540-551.
3. Heizmann, C. W.; Fritz, G.; Schäfer, B. W. S100 proteins: structure, functions and pathology. Front. Biosci. 2002, 7, 1356-1368.
4. Gebhardt, C.; Nemeth, J.; Angel, P.; Hess, J. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 2006, 72, 1622-1631.
5. Odink, K.; Cerletti, N.; Brüggen, J.; Clerc, R. G.; Tarcsay, L.; Zwadlo, G.; Gerhards, G.; Schlegel, R.; Sorg, C. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987, 330, 80-82.
6. Hunter, M. J.; Chazin, W. High level expression and dimmer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J. Biol. Chem. 1998, 273, 12427-12435.
7. Manitz, M. P.; Horst, B.; Seeliger, S.; Strey, A.; Skryabin, B. V.; Gunzer, M.; Frings, W.; Schönlau, F.; Roth, J.; Sorg, C.; Nacken, W. Loss of S100A9(MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 2003, 23, 1034-1043.
8. Hobbs, J. A.; May, R.; Tanousis, K.; McNeill, E.; Mathies, M.; Gebhardt, C.; Henderson, R.; Robinson, M. J.; Hogg, N. Myeloid cell function in MRP-14(S100A9) null mice. Mol. Cell. Biol. 2003, 23, 2564-2576.
9. Gabrielsen, T. O.; Dale, I.; Brandtzaeg, P.; Hoel, P. S.; Fagerhol, M. K.; Larsen, T. E.; Thune, P. O. Epidermal and dermal distribution of a myelomonocytic antigen (L1) shared by epithelial cells in various inflammatory skin diseases. J. Am. Acad. Dermatol. 1986, 15, 173-179.
10. Wilkinson, M. M.; Busuttil, A.; Hayward, C.; Brock, D. J. H.; Dorin, J. R.; van Heyningen, V. Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues. J. Cell. Sci. 1988, 91, 221-230.
11. Goebeler, M.; Roth, J.; van den Bos, C.; Ader, G.; Sorg, C. Increase of calcium levels in epithelial cells induces translocation of calcium-binding proteins migration inhibitory facter-related protein 8(MRP8) and MRP14 to keratin intermediate filaments. Biochem. J. 1995, 309, 419-424.
12. Eckert, R. L.; Broome, A. M.; Ruse, M.; Robinson, N.; Ryan, D.; Lee, K. S100 proteins in the epidermis. J. Invest. Dermatol. 2004, 123, 23-33.
13. Arai, K.; Yamada, T.; Nozawa, R. Immunohistochemical investigation of migration inhibitory factor-related protein(MRP)-14 expression in hepatocellular carcinoma. Med. Oncol. 2000, 17, 183-188.
14. Arai, K.; Teratani, T.; Nozawa, R.; Yamada, T. Immunohistochemical Investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncol. Rep. 2001, 8, 591-596.
15. Arai, K.; Teratani, T.; Kuruto-Niwa, R.; Yamada, T.; Nozawa, R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur. J. Cancer 2004, 40, 1179-1187.
16. Ito, Y.; Arai, K.; Nozawa, R.; Yoshida, H.; Tomoda, C.; Uruno, T.; Miya, A.; Kobayashi, K.; Matsuzuka, F.; Kuma, K.; Kakudo, K.; Miyauchi, A. S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma. Pathol. Pract. Res. 2005, 201, 551-556.
17. Hermani, A.; Hess, J.; De Servi, B.; Medunjanin, S.; Grobholz, R.; Trojan, L.; Angel, P.; Mayer, D. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 2005, 11, 5146-5152.
18. Domoto, T.; Miyama, Y.; Suzuki, H.; Teratani, T.; Arai, K.; Sugiyama, T.; Takayama, T.; Mugiya, S.; Ozono, S.; Nozawa, R. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci. 2006, 98, 77-82.
19. Teratani, T.; Watanabe, T.; Kuwahara, F.; Kumagai, H.; Kobayashi, S.; Aoki, U.; Ishikawa, A.; Arai, K.; Nozawa, R. Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma. Cancer Lett. 2002, 175, 71-77.
20. Teratani, T.; Watanabe, T.; Yamahara, K.; Kumagai, H.; Ishikawa, A.; Arai, K.; Nozawa, R. Restricted expression of calcium-binding protein S100A5 in human kidney. Biochem. Biophys. Res. Commun. 2002, 291, 623-627.
21. Nozawa, R.; Kato, H.; Ito, T.; Yokota, T. Identification and characterization of a differentiation antigen in human neutrophils and monocytes. Blood 1988, 71, 1288-1294.
22. Showji, Y.; Nozawa, R.; Sato, K.; Suzuki, H. Seroprevalence of Helicobacter pylori infection in patients with connective tissue diseases. Microbiol. Immunol. 1996, 40, 499-503.
23. Elston, C. W.; Ellis, I. O. Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19, 403-410.
24. Singletary, S. E.; Allred, C.; Ashley, P.; Bassett, L. W.; Berry, D.; Bland, K. I.; Borgen, P. I.; Clark, G.; Edge, S. B.; Hayes, D. F.; Hughes, L. L.; Hutter, R. V.; Morrow, M.; Page, D. L.; Recht, A.; Theriault, R. L.; Thor, A.; Weaver, D. L.; Wieand, H. S.; Greene, F. L. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 2002, 20, 3628-3636.
25. Holland, R.; Peterse, J. L.; Millis, R. R.; Eusebi, V.; Faverly, D.; van de Vijver, N. J.; Zafrani, B. Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Pathol. 1994, 11, 167-180.
26. Yamamoto, T.; Ikawa, S.; Akiyama, T.; Semba, K.; Nomura, N.; Miyajima, N.; Saito, T.; Toyoshima, K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986, 319, 230-234.
27. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
28. Wang, S. C.; Zhang, L.; Hortobagyi, G. N.; Hung, M. C. Targeting HER2: recent developments and future directions for breast cancer patients. Semin. Oncol. 2001, 28, 21-29.
29. Tsuda, H.; Tani, Y.; Hasegawa, T.; Fukutomi, T. Concordance in judgements among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma. Pathol. Int. 2001, 51, 26-32.
30. Tsuda, H.; Sasano, H.; Akiyama, F.; Kurosumi, M.; Hasegawa, T.; Osamura, R. Y.; Sakamoto, G. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (cerbB-2) expression detected by Hercep Test, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol. Int. 2002, 52, 126-134.
31. Goldhirsch, A.; Coates, A. S.; Gelber, R. D.; Glick, J. H.; Thurlimann, B.; Senn, H. J.; St Gallen expert panel members. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann. Oncol. 2006, 17, 1772-1776.
32. Vogl, T.; Ludwig, S.; Goebeler, M.; Strey, A.; Thorey, I. S.; Reichelt, R.; Foell, D.; Gerke, V.; Manitz, M. P.; Nacken, W.; Werner, S.; Sorg, C.; Roth, J. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004, 104, 4260-4268.
33. Goebeler, M.; Roth, J.; Henseleit, U.; Sunderkotter, C.; Sorg, C. Expression and complex assembly of calcium-binding proteins MRP8 and MRP14 during differentiation of myelomonocytic cells. J. Leukoc. Biol. 1993, 53, 11-18.
34. Vogl, T.; Roth, J.; Sorg, C.; Hillenkamp, F.; Strupat, K. Calcium-induced noncovalently linked tetramers of MRP8 and MRP14 detected by ultraviolet matrix-assisted laser desorption/ionization mass spectrometry. J. Am. Soc. Mass. Spectrom. 1999, 10, 1124-1130.
35. Vogl, T.; Propper, C.; Hartmann, M.; Strey, A.; Strupat, K.; van den Bos, C.; Sorg, C.; Roth, J. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J. Biol. Chem. 1999, 274, 25291-25296.
36. Hermani, A.; De Servi, B.; Medunjanin, S.; Tessier, P. A.; Mayer, D. S100A8 and S100A9 activate MAP kinase and NF-κB signaling pathways and translocation of RAGE in human prostate cancer cells. Exp. Cell. Res. 2006, 312, 184-197.
37. Zwadlo, G.; Brüggen, J.; Gerhards, G.; Schlegel, R.; Sorg, C. Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin. Exp. Immunol. 1988, 72, 510-515.
38. Lagios, M. D.; Margolin, F. R.; Westdahl, P. R.; Rose, M. R. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989, 63, 618-624.
39. Roth, J.; Vogl, T.; Sorg, C.; Sunderkotter, C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends. Immunol. 2003, 24, 155-157.
40. Schmidt, A. M.; Yan, S. D.; Yan, S. F.; Stern, D. M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108, 949-955.
41. Chavakis, T.; Bierhaus, A.; Al-Fakhri, N.; Schneider, D.; Witte, S.; Linn, T.; Nagashima, M.; Morser, J.; Arnold, B.; Preissner, K. T.; Nawroth, P. P. The pattern recognition receptor (RAGE) is a counter-receptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 2003, 198, 1507-1515.
42. Taguchi, A.; Blood, D. C.; del Toro, G.; Canet, A.; Lee, D. C.; Qu, W.; Tanji, N.; Lu, Y.; Lalla, E.; Fu, C.; Hofmann, M. A.; Kislinger, T.; Ingram, M.; Lu, A.; Tanaka, H.; Hori, O.; Ogawa, S.; Stern, D. M.; Schmidt, A. M. Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastasis. Nature 2000, 405, 354-360.
43. Kuniyasu, H.; Chihara, Y.; Kondo, H.; Ohmori, H.; Ukai, R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol. Rep. 2003, 10, 1863-1868.
44. Huttunen, H. J.; Fages, C.; Rauvala, H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 1999, 274, 19919-19924.
45. Inoue, J.; Gohda, J.; Akiyama, T.; Semba, K. NF-κB activation in development and progression of cancer. Cancer Sci. 2007, 98, 268-274.
46. Hiratsuka, S.; Watanabe, A.; Aburatani, H.; Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8, 1369-1375.